Osman Cagin Buldukoglu

Osman Cagin Buldukoglu

Auto-generated profile, based on publicly available information

Osman Cagin Buldukoglu

Department of Gastroenterology, Antalya Training and Research Hospital, University of Health Sciences, Antalya, Turkey

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 July 2020 in International Journal of Gynecology & Obstetrics
Verified
Journal Article
Closed access
PDF file
OBOsman Cagin Buldukoglu
Osman Cagin Buldukoglu
ATAlev Turker
Alev Turker
AUAlp Usubutun
Alp Usubutun
MSMehmet Coskun Salman
Mehmet Coskun Salman

11 January 2024 in Pancreatology
Verified
Journal Article
Closed access
SOSerkan Ocal
Serkan Ocal
KCKubra Cerci
Kubra Cerci
OBOsman Cagin Buldukoglu
Osman Cagin Buldukoglu
GAGalip Egemen Atar
Galip Egemen Atar
FHFerda Akbay Harmandar
Ferda Akbay Harmandar
ACAyhan Hilmi Cekin
Ayhan Hilmi Cekin

15 June 2024 in Turkish Journal of Gastroenterology
Verified
Journal Article
Open access
OBOsman Çağın Buldukoğlu
Osman Çağın Buldukoğlu
SÖSerkan Öcal
Serkan Öcal
GAGalip Egemen Atar
Galip Egemen Atar
FHFerda Akbay Harmandar
Ferda Akbay Harmandar
AÇAyhan Hilmi Çekin
Ayhan Hilmi Çekin
Background/Aims: Diverticulosis coli is a common disorder of the colon, and a luminal pressure increase in the colon is a proposed mechanism in disease pathogenesis. Toilet types used around the world can be fundamentally categorized into 2 categories: sitting toilets and squatting toilets. Squatting toilets are shown to lead to better puborectalis muscle relaxation, wider anorectal angle, and require less straining compared to sitting toilets. Stemming from this knowledge, we hypothesized that toilet type would play a role in the complex pathogenesis of diverticulosis and that squatting toilets would lower the risk of diverticula formation. Materials and Methods: This study was conducted at Antalya Training and Research Hospital between January 2023 and July 2023. A 1-page questionnaire consisting of demographic data and bowel habits as well as diverticulosis-related parameters was prepared to gather the study data. Colonoscopy results were matched with corresponding questionnaires. Results: The study population consisted of 929 patients. Advanced age was found to be a risk factor for diverticulosis. Sitting toilet was also found to be a risk factor for diverticulosis in multivariate logistic regression analysis with an odds ratio of 3.36 (95% CI: 1.684-6.705) (P = .001). Conclusion: The results of this study revealed that toilet type is a determining factor in diverticulosis development, as was hypothesized during the conceptualization of the study. Revealing the potential contribution of the toilet type used to the development of a relatively common and impactful disorder like diverticulosis will lay the bedrock for future studies on the topic. Cite this article as: Buldukoğlu OÇ, Öcal S, Atar GE, Akbay Harmandar F, Çekin AH. Sit or squat? Toilet type is a determinant of diverticulosis development. Turk J Gastroenterol. 2024;35(6):475-480.

1 January 2018 in Sage Open Medicine
Verified
Journal Article
Open access
PDF file
MAMete Akin
Mete Akin
OBOsman Cagin Buldukoglu
Osman Cagin Buldukoglu
HAHaydar Adanir
Haydar Adanir
ISInci Suleymanlar
Inci Suleymanlar
DDDinc Dincer
Dinc Dincer
BYBulent Yildirim
Bulent Yildirim
Objective: Successful treatment is possible with novel direct-acting oral antiviral agents in solid organ transplant patients with hepatitis C. In this study, the effectiveness and safety of sofosbuvir/ledipasvir ± ribavirin treatment in liver and/or renal transplant patients with chronic hepatitis C were evaluated. Materials and methods: A total of 23 liver and/or renal transplant patients who received sofosbuvir/ledipasvir ± ribavirin for chronic hepatitis C over 12 or 24 weeks were enrolled in the study. The treatment response, clinical and laboratory adverse effects, and effect on immunosuppressive drug levels were assessed. Results: A total of 12 patients had undergone renal transplantation and 11 had undergone liver transplantation. All of the renal transplant patients and 91% of liver transplant patients had genotype 1. In total, 10 renal transplant patients and 4 liver transplant patients had treatment experience. Two renal transplant patients and one liver transplant patient had compensated cirrhosis. Nine renal transplant patients were on tacrolimus, and two were on cyclosporine; all of the liver transplant patients were on tacrolimus-based immunosuppressive therapy. While hepatitis C RNA was negative in 75% of renal transplant patients and 91% of liver transplant patients at week 4, it was negative in all of the patients at the end of treatment and 12 weeks after treatment. Significantly reduced hemoglobin levels were observed in patients administered ribavirin during treatment (p = 0.01). There were no significant differences between the baseline and treatment period values of mean creatinine, estimated glomerular filtration rate, bilirubin, and tacrolimus levels. There were no adverse effects leading to treatment discontinuation. Conclusion: Sofosbuvir/ledipasvir ± ribavirin is quite safe and effective in hepatitis C treatment after liver and/or renal transplantation.

30 May 2025 in BMC Gastroenterology
Verified
Journal Article
Open access
PDF file
OBOsman Cagin Buldukoglu
Osman Cagin Buldukoglu
SOSerkan Ocal
Serkan Ocal
SASerdar Akca
Serdar Akca
GAGalip Egemen Atar
Galip Egemen Atar
BKBesir Kaya
Besir Kaya
ACAyhan Hilmi Cekin
Ayhan Hilmi Cekin
Ulcerative colitis (UC) is a chronic inflammatory disease with a worldwide prevalance of around 5 million patients. Assessment of disease activity is crucial in management of UC patients. Gasdermin D (GSDMD) is a protein which belongs to the gasdermin protein family and plays a role in inflammatory cell death, pyroptosis. GSDMD activation has been shown to be related to inflammatory states in a variety of disorders, including inflammatory bowel diseases. With this study, we aimed to reveal a potential new inflammatory serum marker for assessing disease activity and severity in UC patients in a non-invasive manner. This prospective study was carried out at Antalya Training and Research Hospital, Turkey, between September 2022 and March 2024. 93 UC patients were enrolled in the study. Patient and disease characteristics, laboratory workout data, and severity indexes comprising Truelove and Witts’ severity index (TWSI) and Mayo endoscopic subscore (MES) were analyzed with serum GSDMD levels. GSDMD, CRP (C-reactive protein), and body-mass index were statistically significant independent predictors of increasing disease severity according to TWSI. GSDMD and CRP were statistically significant independent predictors of higher MES scores. GSDMD demonstrated excellent discriminative performance in distinguishing patients with moderate-to-severe MES from those with normal or mild MES, with an area under the curve value of 0.976. A cut-off value of 6.0 ng/mL for GSDMD was identified as optimal, yielding a sensitivity of 95.0%, a specificity of 86.3%, and a Youden Index of 0.813. The results of the study revealed that GSDMD is a robust biomarker in predicting a more severe disease state for UC in terms of TWSI and MES, putting this novel protein into highlight as a potential new biomarker in patients with UC.

1 January 2013 in Sao Paulo Medical Journal
Verified
Journal Article
Open access
PDF file
MTMine Durusu Tanriover
Mine Durusu Tanriover
GGGoksel Guven
Goksel Guven
CBCagin Buldukoglu
Cagin Buldukoglu
ODOmer Diker
Omer Diker
BHBurcin Halacli
Burcin Halacli
ATArzu Topeli
Arzu Topeli
Patients admitted to non-internal medicine wards may even be in greater need of general medical care. We conducted a one-day cross-sectional survey to gather data on all the adult patients admitted to the wards (excluding intensive care and coronary care units and internal medicine wards) of a university hospital. There were 301 patients in the non-internal medicine, non-intensive care wards on a single day. The mean age of the patients was 50.5 ± 18.1 years (range: 16 to 92 years). More than 60% of the patients had been admitted for elective surgery ( Table 1 ). Seventy-three percent of the patients (n = 220) presented at least one medical comorbidity and a median of two drugs (minimum 0; maximum 12) on the medication list ( Table 1 ).